Augmenting transgene expression from carcinoembryonic antigen (CEA) promoter via a GAL4 gene regulatory system

Patricia E. Koch, Z. Sheng Guo, Shunsuke Kagawa, Jian Gu, Jack A. Roth, Bingliang Fang

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

Though extensively studied, the use of tissue- or cell-type-specific promoters to target transgene expression is hampered by their weak activity. We hypothesized that this problem could be addressed by using a GAL4 gene regulatory system, wherein a weak, tissue-specific promoter would drive expression of the GAL4/VP16 fusion protein (GV16), which in turn would transactivate a minimal synthetic promoter, GAL4/TATA (GT), upstream of a transgene. To test this hypothesis, we constructed adenoviral vectors expressing a lacZ or GV16 gene driven by a carcinoembryonic antigen (CEA) promoter (Ad/CEA-LacZ or Ad/CEA-GV16) and evaluated levels of transgene expression they produced in cultured cells and in subcutaneous tumors after intratumoral administration. In CEA-positive cells, treatment with Ad/CEA-GV16 + Ad/GT-LacZ versus Ad/CEA-LacZ increased transgene expression 20- to 100-fold. In CEA-negative cells, treatment with Ad/CEA-GV16 + Ad/GT-LacZ increased transgene expression to a much lower degree (6- to 8-fold). In addition, analysis of Bax gene-mediated cell death revealed that this system can be used to avoid Bax's toxic effects on CEA-negative cells without compromising its ability to kill CEA-positive cells in vitro and in vivo. Thus, the combination of a tissue-specific promoter with the GAL4 gene regulatory system could be useful for targeting transgene expression.

Original languageEnglish
Pages (from-to)278-283
Number of pages6
JournalMolecular Therapy
Volume3
Issue number3
DOIs
Publication statusPublished - 2001
Externally publishedYes

Fingerprint

Carcinoembryonic Antigen
Regulator Genes
Transgenes
Herpes Simplex Virus Protein Vmw65
Poisons
Genes
Cultured Cells
Cell Death

Keywords

  • Bax
  • Gene therapy
  • Tissue-specific expression
  • Tumor

ASJC Scopus subject areas

  • Molecular Biology

Cite this

Augmenting transgene expression from carcinoembryonic antigen (CEA) promoter via a GAL4 gene regulatory system. / Koch, Patricia E.; Guo, Z. Sheng; Kagawa, Shunsuke; Gu, Jian; Roth, Jack A.; Fang, Bingliang.

In: Molecular Therapy, Vol. 3, No. 3, 2001, p. 278-283.

Research output: Contribution to journalArticle

Koch, Patricia E. ; Guo, Z. Sheng ; Kagawa, Shunsuke ; Gu, Jian ; Roth, Jack A. ; Fang, Bingliang. / Augmenting transgene expression from carcinoembryonic antigen (CEA) promoter via a GAL4 gene regulatory system. In: Molecular Therapy. 2001 ; Vol. 3, No. 3. pp. 278-283.
@article{5f148db2fcf148f58c78217c231381cb,
title = "Augmenting transgene expression from carcinoembryonic antigen (CEA) promoter via a GAL4 gene regulatory system",
abstract = "Though extensively studied, the use of tissue- or cell-type-specific promoters to target transgene expression is hampered by their weak activity. We hypothesized that this problem could be addressed by using a GAL4 gene regulatory system, wherein a weak, tissue-specific promoter would drive expression of the GAL4/VP16 fusion protein (GV16), which in turn would transactivate a minimal synthetic promoter, GAL4/TATA (GT), upstream of a transgene. To test this hypothesis, we constructed adenoviral vectors expressing a lacZ or GV16 gene driven by a carcinoembryonic antigen (CEA) promoter (Ad/CEA-LacZ or Ad/CEA-GV16) and evaluated levels of transgene expression they produced in cultured cells and in subcutaneous tumors after intratumoral administration. In CEA-positive cells, treatment with Ad/CEA-GV16 + Ad/GT-LacZ versus Ad/CEA-LacZ increased transgene expression 20- to 100-fold. In CEA-negative cells, treatment with Ad/CEA-GV16 + Ad/GT-LacZ increased transgene expression to a much lower degree (6- to 8-fold). In addition, analysis of Bax gene-mediated cell death revealed that this system can be used to avoid Bax's toxic effects on CEA-negative cells without compromising its ability to kill CEA-positive cells in vitro and in vivo. Thus, the combination of a tissue-specific promoter with the GAL4 gene regulatory system could be useful for targeting transgene expression.",
keywords = "Bax, Gene therapy, Tissue-specific expression, Tumor",
author = "Koch, {Patricia E.} and Guo, {Z. Sheng} and Shunsuke Kagawa and Jian Gu and Roth, {Jack A.} and Bingliang Fang",
year = "2001",
doi = "10.1006/mthe.2001.0273",
language = "English",
volume = "3",
pages = "278--283",
journal = "Molecular Therapy",
issn = "1525-0016",
publisher = "Nature Publishing Group",
number = "3",

}

TY - JOUR

T1 - Augmenting transgene expression from carcinoembryonic antigen (CEA) promoter via a GAL4 gene regulatory system

AU - Koch, Patricia E.

AU - Guo, Z. Sheng

AU - Kagawa, Shunsuke

AU - Gu, Jian

AU - Roth, Jack A.

AU - Fang, Bingliang

PY - 2001

Y1 - 2001

N2 - Though extensively studied, the use of tissue- or cell-type-specific promoters to target transgene expression is hampered by their weak activity. We hypothesized that this problem could be addressed by using a GAL4 gene regulatory system, wherein a weak, tissue-specific promoter would drive expression of the GAL4/VP16 fusion protein (GV16), which in turn would transactivate a minimal synthetic promoter, GAL4/TATA (GT), upstream of a transgene. To test this hypothesis, we constructed adenoviral vectors expressing a lacZ or GV16 gene driven by a carcinoembryonic antigen (CEA) promoter (Ad/CEA-LacZ or Ad/CEA-GV16) and evaluated levels of transgene expression they produced in cultured cells and in subcutaneous tumors after intratumoral administration. In CEA-positive cells, treatment with Ad/CEA-GV16 + Ad/GT-LacZ versus Ad/CEA-LacZ increased transgene expression 20- to 100-fold. In CEA-negative cells, treatment with Ad/CEA-GV16 + Ad/GT-LacZ increased transgene expression to a much lower degree (6- to 8-fold). In addition, analysis of Bax gene-mediated cell death revealed that this system can be used to avoid Bax's toxic effects on CEA-negative cells without compromising its ability to kill CEA-positive cells in vitro and in vivo. Thus, the combination of a tissue-specific promoter with the GAL4 gene regulatory system could be useful for targeting transgene expression.

AB - Though extensively studied, the use of tissue- or cell-type-specific promoters to target transgene expression is hampered by their weak activity. We hypothesized that this problem could be addressed by using a GAL4 gene regulatory system, wherein a weak, tissue-specific promoter would drive expression of the GAL4/VP16 fusion protein (GV16), which in turn would transactivate a minimal synthetic promoter, GAL4/TATA (GT), upstream of a transgene. To test this hypothesis, we constructed adenoviral vectors expressing a lacZ or GV16 gene driven by a carcinoembryonic antigen (CEA) promoter (Ad/CEA-LacZ or Ad/CEA-GV16) and evaluated levels of transgene expression they produced in cultured cells and in subcutaneous tumors after intratumoral administration. In CEA-positive cells, treatment with Ad/CEA-GV16 + Ad/GT-LacZ versus Ad/CEA-LacZ increased transgene expression 20- to 100-fold. In CEA-negative cells, treatment with Ad/CEA-GV16 + Ad/GT-LacZ increased transgene expression to a much lower degree (6- to 8-fold). In addition, analysis of Bax gene-mediated cell death revealed that this system can be used to avoid Bax's toxic effects on CEA-negative cells without compromising its ability to kill CEA-positive cells in vitro and in vivo. Thus, the combination of a tissue-specific promoter with the GAL4 gene regulatory system could be useful for targeting transgene expression.

KW - Bax

KW - Gene therapy

KW - Tissue-specific expression

KW - Tumor

UR - http://www.scopus.com/inward/record.url?scp=0034989410&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034989410&partnerID=8YFLogxK

U2 - 10.1006/mthe.2001.0273

DO - 10.1006/mthe.2001.0273

M3 - Article

C2 - 11273768

AN - SCOPUS:0034989410

VL - 3

SP - 278

EP - 283

JO - Molecular Therapy

JF - Molecular Therapy

SN - 1525-0016

IS - 3

ER -